← Back to Clinical Trials
Recruiting NCT06557499

NCT06557499 A 3-way Crossover Clinical Investigation to Assess the Performance of Two Different Sized Polyurethane Condoms Versus a Latex Condom in Healthy Monogamous Couples.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06557499
Status Recruiting
Phase
Sponsor Reckitt Benckiser Healthcare (UK) Limited
Condition Contraception
Study Type INTERVENTIONAL
Enrollment 600 participants
Start Date 2024-08-23
Primary Completion 2025-05-19

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Polyurethane (PU) male condom-Test condom 1Polyurethane (PU) male condom-Test condom 2Natural Rubber Latex (NRL) male condom- Control condom

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 600 participants in total. It began in 2024-08-23 with a primary completion date of 2025-05-19.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This investigation is designed to evaluate the performance rate of two polyurethane male condoms with different sizes and thicknesses versus a standard natural rubber latex (NRL) male condom. The purpose of this study is to see how well the experimental condoms perform compared to the latex rubber condom (for example, how often the different condom types break or slip off the penis). Sponsor also wants to find out how well couples like using the three condom types and whether they experience any problems when using the condoms (for example, irritation or discomfort).

Eligibility Criteria

Inclusion Criteria: 1. Both partners participating must provide written informed consent. 2. Couples must include a male and female within a heterosexual couple and be between 18 - 60 years of age inclusive. 3. Both partners must be willing to respond to questions about their reproductive and contraceptive history and use of condoms during interviews and respond to self-administered questionnaires as per instructions. 4. Both partners must agree to answer the questions in the condom use questionnaires and two scales as soon as possible and within 2 (+6) hours following each coital act. 5. Both partners must be generally healthy and in a mutually monogamous heterosexual relationship - current relationship ≥ 3 months. 6. All couples must be averaging one act of intercourse weekly, agree to have penile-vaginal intercourse with a frequency sufficient to meet CIP requirements (a minimum of 5 coital acts over 5 weeks per assessment period-). 7. The female partner must also use an established (as agreed by the Investigator) other highly effective form of non-barrier contraception, unless post-menopausal (confirmed menopausal prior to screening, amenorrhea for at least 12 months after cessation of exogenous hormone treatment) in which case no second form of contraception is required. Highly effective non-barrier contraception includes oral contraceptive (oestrogen and progestogen or progestogen-only hormonal contraception associated with inhibition of ovulation), intra-uterine device (IUD) or intra-uterine system (IUS), hormonal implant, injectables, patch and or sterilization of at least one partner (i.e., bilateral tubal ligation, vasectomy deemed medically successful). 8. Both partners must be able to understand instructions for correct use of condoms. 9. Both partners must have an adequate level of literacy to understand and to be able to answer the questionnaires. 10. Both partners must agree to use only the investigational condoms during the time of participation. 11. Participants must agree to use the penis measuring kit provided to measure the erect penis at investigation start. 12. Both partners must agree not to use drugs or non-investigational devices that can affect sexual performance. 13. Both partners must have no known sexually transmitted infections including Human Immunodeficiency Virus (HIV) / acquired immune deficiency syndrome (AIDS) (medical history via self-report) (uncomplicated Herpes simplex virus (HSV) and positive Human papillomavirus (HPV) which areis asymptomatic may be included in the investigation study in the opinion of the Investigator). 14. Both partners must agree to use only lubricant(s) provided for the duration of investigation. 15. Both partners must agree not to wear any genital piercing jewellery for the duration of the clinical investigation. 16. Both partners must have no past medical history of any health condition (self-reported) that, in the opinion of the Investigator, would be considered clinically relevant. 17. Couples must have a compatible electronic device with internet access which they are willing to upload questionnaire data to the web-based platform throughout the investigation. 18. Both partners will be available for follow-up. Exclusion Criteria: 1. Either partner is or becomes aware of an allergy or sensitivity to the ingredients of any of the products, including the test or control condoms or any lubrication products provided. 2. Either partner has been receiving daily treatment for their pre-existing skin condition (for example, severe eczema/psoriasis) within the three months prior to the screening for this study. 3. Female partner that is pregnant or desires to become so while participating in investigation, (females of childbearing potential must have a negative pregnancy test as part of screening). 4. Any couple undergoing any form of fertility treatment such as in-vitro fertilisation. 5. Either partner needs to use condoms for sexually transmitted infection (STI) protection (e.g., discordance for Human Immunodeficiency Virus (HIV) or herpes). 6. Either partner has previous or planned genital surgery that in the opinion of the Investigator would consider the participant unsuitable to participate in the clinical investigation (e.g., laser for abnormal smear). 7. Either partner are commercial sex workers. 8. Either partner are itinerant persons who will be unable to complete the clinical investigation (e.g., migrant farm workers). 9. Couples that in the opinion of the Investigator, would be unable to complete the investigation. 10. Male partners that have known erectile or ejaculatory dysfunction in the past month. 11. Either partner requires to use/ is using medication or preparations that are applied topically to the genitalia area or intravaginally, other than that supplied for the investigation. 12. A female partner that has been diagnosed with or treated for vaginal complaints (including vaginal dryness) in the previous 3 months which, in the opinion of the Investigator, deems the partner unsuitable for the investigation. 13. Either partner uses any medication which in the investigator's opinion may interfere with the use of condoms. 14. A male partner with abnormal penile anatomy or genital lesion (e.g., balanoposthitis) that would, in the opinion of the Investigator, affect the ability to keep the condom in place during intercourse. 15. Either partner is suffering from any health conditions (self-reported) or any condition which could, in the opinion of the Investigator, affect the outcome of the investigation or affect their safety if they participate. 16. Either partner have participated in a clinical trial in the previous month which could, in the opinion of the Investigator, affect the outcome of the investigation. 17. Either partner is an employee of the investigational Sponsor or affiliated with the clinical research centre (i.e., enrolment of the Investigator, his/ her family members, employees and other dependent persons). 18. Either partner has a recent history of drug/alcohol abuse within the previous 12 months. 19. Either partner has an inability to follow the procedures of the investigation, (e.g., due to language problems, psychological disorders, health conditions such as dementia). 20. Either partner is unable, in the opinion of the Investigator, to fully comply with the investigation requirements.

Contact & Investigator

Central Contact

Terri Walsh

✉ twalsh@essentialaccess.org

📞 +1 213 386 5614

Principal Investigator

Terri Walsh

PRINCIPAL INVESTIGATOR

Essential Access Health

Frequently Asked Questions

Who can join the NCT06557499 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Contraception. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06557499 currently recruiting?

Yes, NCT06557499 is actively recruiting participants. Contact the research team at twalsh@essentialaccess.org for enrollment information.

Where is the NCT06557499 trial being conducted?

This trial is being conducted at Berkeley, United States, Los Angeles, United States, Seattle, United States.

Who is sponsoring the NCT06557499 clinical trial?

NCT06557499 is sponsored by Reckitt Benckiser Healthcare (UK) Limited. The principal investigator is Terri Walsh at Essential Access Health. The trial plans to enroll 600 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology